Skip to main content
SpringerLink
Log in

Effect of Zileuton on Theophylline Pharmacokinetics

  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

In controlled trials involving asthma patients, zileuton — a selective 5-lipoxygenase inhibitor — has significantly improved pulmonary function and reduced symptoms. Since theophylline is frequently prescribed for asthma, we designed a placebo-controlled randomised crossover trial to examine the influence of zileuton on theophylline pharmacokinetics.

16 healthy adult males were given theophylline (Slo-Phyllin® ) 200mg 4 times daily for 5 days and either zileuton 800mg twice daily or a matching placebo. After a 15-day washout period, theophylline was resumed and the other study drugs reversed. During coadministration with zileuton, mean peak theophylline levels rose from 12.14 to 20.99 mg/L (p < 0.001), while the apparent plasma clearance dropped from 3.74 to 1.91 L/h (p < 0.001). The time to the peak theophylline concentration was delayed by 0.5 hours and the half-life was significantly prolonged by 1.5 hours. 14 volunteers reported 44 mild or moderately severe adverse events, possibly or probably related to coadministration of zileuton, and 8 volunteers reported 8 such events with placebo coadministration. Three volunteers receiving theophylline plus zileuton withdrew from the trial prematurely.

Thus, a pharmacokinetic interaction that may produce theophylline toxicity exists between zileuton and theophylline. Accordingly, theophylline dosages in patients receiving zileuton should be adjusted to maintain levels within the therapeutic range. Upon initiation of zileuton, the typical asthma patient may require dosage reductions of one-half, and monitoring of plasma theophylline concentrations is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adelroth E, Morris MM, Hargreave FE, et al. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986; 315:480–4

    Article  PubMed  CAS  Google Scholar 

  2. Barnes NC, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax 1984; 39: 500–4

    Article  PubMed  CAS  Google Scholar 

  3. Holroyde MC, Altounyan REC, Cole M, et al. Bronchoconstriction produced in man by leukotrienes C and D. Lancet 1981; 2: 17–8

    Article  PubMed  CAS  Google Scholar 

  4. Marom Z, Shelhamer JH, Bach MK, et al. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Resp Dis 1982; 126: 449–51

    PubMed  CAS  Google Scholar 

  5. Smith LJ, Greenberger PA, Patterson R, et al. The effect of inhaled leukotriene D4 in humans. Am Rev Resp Dis 1985; 131:368–72

    PubMed  CAS  Google Scholar 

  6. Weiss JW, Drazen JM, Coles N, et al. Bronchoconstrictor effects of leukotriene C in humans. Science 1982; 216: 196–8

    Article  PubMed  CAS  Google Scholar 

  7. Bell RL, Young PR, Albert D, et al. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol 1992; 14: 505–10

    Article  PubMed  CAS  Google Scholar 

  8. Carter GW, Young PR, Albert DH, et al. 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 1991; 256: 929–37

    PubMed  CAS  Google Scholar 

  9. Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46: 184–9

    Article  PubMed  CAS  Google Scholar 

  10. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323: 1740–4

    Article  PubMed  CAS  Google Scholar 

  11. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059–66

    PubMed  CAS  Google Scholar 

  12. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990; 323: 1745–8

    Article  PubMed  CAS  Google Scholar 

  13. Rubin P, Dubé L, Braeckman R, et al. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. Agents Actions 1991; 35: 103–16

    CAS  Google Scholar 

  14. Granneman GR, Braeckman RA, Erdman KA. Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography. Clin Pharmacokinet 1995; 29 Suppl. 2: 1–8

    Article  PubMed  CAS  Google Scholar 

  15. Sweeney DJ, Bouska J, Machinist J, et al. Glucuronidation of zileuton (A-64077) by human hepatic microsomes. Drug Metab Dispos 1992; 20: 328–9

    Google Scholar 

  16. Lesko LJ. Dose-dependent elimination kinetics of theophylline. Clin Pharmacokinet 1979; 4: 449–59

    Article  PubMed  CAS  Google Scholar 

  17. Tang-Liu DD-S, Williams RL, Riegelman S. Nonlinear theophylline elimination. Clin Pharmacol Ther 1982; 31: 358–69

    Article  PubMed  CAS  Google Scholar 

  18. Tang-Liu DD-S, Tozer TN, Riegelman S. Urine flow-dependence of theophylline renal clearance in man. J Pharmacokinet Biopharm 1982; 10:351–63

    PubMed  CAS  Google Scholar 

  19. Tang-Liu DD-S, Williams RL. A composite view of theophylline elimination in man, in pharmacokinetics — a modern view. Benet LZ, Levy G, Ferraiolo BL, editors. New York: Plenum Press, 1984

  20. Jonkman JHG, Tang D, Upton RA, et al. Measurement of excretion characteristics of theophylline and its major metabolites. Eur J Clin Pharmacol 1981; 20: 435–41

    Article  PubMed  CAS  Google Scholar 

  21. Sarker MA, Hunt C, Guzelian PS, et al. Characterisation of human liver cytochrome P-450 involved in theophylline metabolism. Drug Metab Dispos 1992; 20: 31–7

    Google Scholar 

  22. Sarker MA, Jackson BJ. Theophylline N-demethylations as probes for P450 1A1 and P450 1A2. Drug Metab Dispos 1994; 22: 827–34

    Google Scholar 

  23. Branigan TA, Robins RA, Cady WJ, et al. The effects of erythromycin on the absorption and disposition kinetics of theophylline. Eur J Clin Pharmacol 1981; 21: 115–20

    Article  PubMed  CAS  Google Scholar 

  24. Weinberger M, Hudgel D, Spector S, et al. Inhibition of theophylline clearance by troleandomycin. J Allergy Clin Immunol 1977; 59: 228–31

    Article  PubMed  CAS  Google Scholar 

  25. Cremer KF, Secor J, Speeg KV. The effect of route of administration on the cimetidine-theophylline drug interaction. J Clin Pharmacol 1989; 29: 451–6

    PubMed  CAS  Google Scholar 

  26. Sörgel F, Mahr G, Granneman GR, et al. Effects of two quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics. Clin Pharmacokinet 1992; 22 (Suppl. 1): 65–74

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abbott Laboratories D4PK, AP13A, 100 Abbott Park Road, Abbott Park, Illinois, 60064-3500, USA

    G. Richard Granneman, Rene A. Braeckman, Charles S. Locke, John H. Cavanaugh, Louise M. Dubé & Walid M. Awni

Authors
  1. G. Richard Granneman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rene A. Braeckman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles S. Locke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John H. Cavanaugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Louise M. Dubé
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Walid M. Awni
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Granneman, G.R., Braeckman, R.A., Locke, C.S. et al. Effect of Zileuton on Theophylline Pharmacokinetics. Clin-Pharmacokinet 29 (Suppl 2), 77–83 (1995). https://doi.org/10.2165/00003088-199500292-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199500292-00011

Keywords

Search

Navigation